You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMirtazapine
Accession NumberDB00370  (APRD00685)
TypeSmall Molecule
GroupsApproved
Description

Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. [Wikipedia]

Structure
Thumb
Synonyms
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine
6-Azamianserin
Mepirzapine
Mirtazapin
Mirtazapina
Mirtazapine
Mirtazapinum
External Identifiers
  • Org 3770
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-mirtazapinetablet45 mgoralAuro Pharma Inc2013-10-16Not applicableCanada
Auro-mirtazapinetablet30 mgoralAuro Pharma Inc2013-10-16Not applicableCanada
Auro-mirtazapinetablet15 mgoralAuro Pharma Inc2013-10-16Not applicableCanada
Auro-mirtazapine ODtablet (orally disintegrating)45 mgoralAuro Pharma Inc2010-12-20Not applicableCanada
Auro-mirtazapine ODtablet (orally disintegrating)30 mgoralAuro Pharma Inc2010-12-20Not applicableCanada
Auro-mirtazapine ODtablet (orally disintegrating)15 mgoralAuro Pharma Inc2010-12-20Not applicableCanada
Ava-mirtazapinetablet30 mgoralAvanstra Inc2011-08-182014-08-21Canada
Ava-mirtazapinetablet15 mgoralAvanstra Inc2011-08-182014-08-21Canada
Co Mirtazapinetablet30 mgoralCobalt Pharmaceuticals Company2006-03-232013-07-19Canada
Dom-mirtazapinetablet15 mgoralDominion Pharmacal2006-08-02Not applicableCanada
Dom-mirtazapinetablet30 mgoralDominion Pharmacal2004-05-27Not applicableCanada
Gd-mirtazapine ODtablet (orally disintegrating)15 mgoralGenmed A Division Of Pfizer Canada Inc2012-04-262014-12-08Canada
Gd-mirtazapine ODtablet (orally disintegrating)30 mgoralGenmed A Division Of Pfizer Canada Inc2012-05-042014-12-08Canada
Gd-mirtazapine ODtablet (orally disintegrating)45 mgoralGenmed A Division Of Pfizer Canada Inc2012-04-262014-12-08Canada
Jamp-mirtazapinetablet15 mgoralJamp Pharma Corporation2011-10-13Not applicableCanada
Jamp-mirtazapinetablet30 mgoralJamp Pharma Corporation2011-10-13Not applicableCanada
Mirtazapinetablet, orally disintegrating15 mg/1oralPrasco Laboratories2001-01-122016-04-05Us
Mirtazapinetablet, orally disintegrating45 mg/1oralPhysicians Total Care, Inc.2012-12-072016-04-05Us
Mirtazapinetablet30 mgoralMeliapharm Inc2004-04-142014-06-25Canada
Mirtazapinetablet15 mgoralMeliapharm Inc2006-07-212014-06-25Canada
Mirtazapinetablet30 mgoralSanis Health Inc2011-09-21Not applicableCanada
Mirtazapinetablet, orally disintegrating45 mg/1oralPrasco Laboratories2001-01-122016-04-05Us
Mirtazapinetablet, orally disintegrating30 mg/1oralPrasco Laboratories2001-01-122016-04-05Us
Mirtazapine - 15tablet15 mgoralPro Doc Limitee2007-10-262008-07-10Canada
Mirtazapine - 30tablet30 mgoralPro Doc Limitee2007-10-262008-07-10Canada
Mirtazapine - 45tablet45 mgoralPro Doc Limitee2007-10-262009-07-23Canada
Mylan-mirtazapinetablet45 mgoralMylan Pharmaceuticals Ulc2004-08-17Not applicableCanada
Mylan-mirtazapinetablet30 mgoralMylan Pharmaceuticals Ulc2004-08-17Not applicableCanada
Mylan-mirtazapinetablet15 mgoralMylan Pharmaceuticals Ulc2004-08-17Not applicableCanada
Ntp-mirtazapinetablet30 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-mirtazapine Od Tabletstablet (orally disintegrating)15 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-mirtazapine Od Tabletstablet (orally disintegrating)45 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-mirtazapine Od Tabletstablet (orally disintegrating)30 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-mirtazapinetablet45 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-mirtazapinetablet30 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-mirtazapinetablet15 mgoralNu Pharm IncNot applicableNot applicableCanada
PMS-mirtazapinetablet15 mgoralPharmascience Inc2005-11-30Not applicableCanada
PMS-mirtazapinetablet30 mgoralPharmascience Inc2004-01-14Not applicableCanada
Pro-mirtazapinetablet30 mgoralPro Doc Limitee2008-07-10Not applicableCanada
Pro-mirtazapinetablet15 mgoralPro Doc Limitee2008-07-10Not applicableCanada
Ratio-mirtazapinetablet30 mgoralRatiopharm Inc Division Of Teva Canada Limited2005-09-292014-09-19Canada
Remerontablet, film coated15 mg/1oralOrganon USA Inc.1996-06-142016-04-23Us
Remerontablet, film coated15 mg/1oralPhysicians Total Care, Inc.2001-03-202016-04-05Us
Remerontablet, film coated45 mg/1oralOrganon USA Inc.1997-03-112016-04-23Us
Remerontablet30 mgoralMerck Canada Inc2001-05-24Not applicableCanada
Remerontablet, film coated30 mg/1oralOrganon USA Inc.1996-06-142016-04-23Us
Remeron Rdtablet (orally disintegrating)45 mgoralMerck Canada Inc2003-12-22Not applicableCanada
Remeron Rdtablet (orally disintegrating)30 mgoralMerck Canada Inc2003-12-22Not applicableCanada
Remeron Rdtablet (orally disintegrating)15 mgoralMerck Canada Inc2003-12-22Not applicableCanada
Remeronsoltabtablet, orally disintegrating45 mg/1oralOrganon USA Inc.2001-01-122016-04-23Us
Remeronsoltabtablet, orally disintegrating30 mg/1oralOrganon USA Inc.2001-01-122016-04-23Us
Remeronsoltabtablet, orally disintegrating15 mg/1oralOrganon USA Inc.2001-01-122016-04-23Us
Riva-mirtazapinetablet30 mgoralLaboratoire Riva Inc2005-03-16Not applicableCanada
Sandoz Mirtazapinetablet30 mgoralSandoz Canada Incorporated2004-03-31Not applicableCanada
Sandoz Mirtazapinetablet15 mgoralSandoz Canada Incorporated2004-03-31Not applicableCanada
Sandoz Mirtazapine Fctablet30 mgoralSandoz Canada Incorporated2005-05-092009-08-06Canada
Teva-mirtazapinetablet30 mgoralTeva Canada Limited2005-10-22Not applicableCanada
Teva-mirtazapine ODtablet (orally disintegrating)15 mgoralTeva Canada Limited2006-08-30Not applicableCanada
Teva-mirtazapine ODtablet (orally disintegrating)45 mgoralTeva Canada Limited2006-08-30Not applicableCanada
Teva-mirtazapine ODtablet (orally disintegrating)30 mgoralTeva Canada Limited2006-08-30Not applicableCanada
Zym-mirtazapinetablet30 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Zym-mirtazapinetablet15 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mirtazapinetablet45 mgoralApotex Inc2006-10-04Not applicableCanada
Apo-mirtazapinetablet30 mgoralApotex Inc2006-10-04Not applicableCanada
Apo-mirtazapinetablet15 mgoralApotex Inc2006-10-04Not applicableCanada
Mirtazapinetablet, orally disintegrating45 mg/1oralbryant ranch prepack2005-12-082016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralProficient Rx LP2007-08-222016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralAmerican Health Packaging2005-10-312016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralH.J. Harkins Company, Inc.2009-08-172016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2015-03-092016-04-05Us
Mirtazapinetablet, orally disintegrating30 mg/1oralAurobindo Pharma Limited2005-12-082016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-08-172016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralAvera Mc Kennan Hospital2015-03-052016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-08-072016-04-05Us
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-07-122016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralMajor Pharmaceuticals2007-08-222016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralActavis Pharma, Inc.2003-06-192016-04-23Us
Mirtazapinetablet, film coated45 mg/1oralAmerican Health Packaging2005-12-212016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralEon Labs, Inc.2003-06-192016-04-23Us
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-07-072016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralTeva Pharmaceuticals USA Inc2003-01-292016-04-23Us
Mirtazapinetablet, film coated45 mg/1oralRebel Distributors Corp.2004-10-222016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-08-172016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralAurolife Pharma LLC2009-08-172016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralCardinal Health2009-08-172016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralAidarex Pharmaceuticals LLC2009-08-172016-04-05Us
Mirtazapinetablet, orally disintegrating15 mg/1oralActavis Pharma, Inc.2014-02-112016-04-23Us
Mirtazapinetablet30 mg/1oralPhysicians Total Care, Inc.2005-10-072016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralApotex Corp.2007-08-222016-04-05Us
Mirtazapinetablet15 mg/1oralState of Florida DOH Central Pharmacy2009-07-012016-04-05Us
Mirtazapinetablet, orally disintegrating30 mg/1oralCitron Pharma LLC2005-12-082016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralCardinal Health2009-08-172016-04-05Us
Mirtazapinetablet, orally disintegrating45 mg/1oralbryant ranch prepack2006-02-282016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralProficient Rx LP2009-08-172016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralAmerican Health Packaging2005-10-312016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2013-05-082016-04-05Us
Mirtazapinetablet, orally disintegrating15 mg/1oralAurobindo Pharma Limited2005-12-082016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2012-09-102016-04-05Us
Mirtazapinetablet30 mg/1oralCardinal Health2009-11-302015-12-29Us
Mirtazapinetablet, film coated30 mg/1oralActavis Pharma, Inc.2003-06-192016-04-23Us
Mirtazapinetablet, film coated30 mg/1oralKAISER FOUNDATION HOSPITALS2010-10-072016-04-23Us
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2011-03-312016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralRebel Distributors Corp.2004-10-222016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralPd Rx Pharmaceuticals, Inc.2003-06-192016-04-05Us
Mirtazapinetablet, film coated7.5 mg/1oralAurolife Pharma LLC2009-08-172016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralCardinal Health2003-01-292016-04-05Us
Mirtazapinetablet45 mg/1oralState of Florida DOH Central Pharmacy2009-07-012016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralApotex Corp.2007-08-222016-04-05Us
Mirtazapinetablet, orally disintegrating15 mg/1oralCitron Pharma LLC2005-12-082016-04-05Us
Mirtazapinetablet, orally disintegrating30 mg/1oralbryant ranch prepack2005-12-082016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralProficient Rx LP2003-01-292016-04-05Us
Mirtazapinetablet45 mg/1oralContract Pharmacy Services Pa2010-06-302016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralREMEDYREPACK INC.2013-03-292016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralAurobindo Pharma Limited2004-10-222016-04-05Us
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2012-03-262016-04-05Us
Mirtazapinetablet15 mg/1oralCardinal Health2009-11-302015-12-29Us
Mirtazapinetablet, film coated15 mg/1oralActavis Pharma, Inc.2003-06-192016-04-23Us
Mirtazapinetablet, film coated15 mg/1oralKAISER FOUNDATION HOSPITALS2011-05-242016-04-23Us
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-03-302016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralRebel Distributors Corp.2004-10-222016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralRebel Distributors Corp2003-06-192016-04-05Us
Mirtazapinetablet, film coated7.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-08-172016-04-23Us
Mirtazapinetablet, film coated15 mg/1oralCardinal Health2003-01-292016-04-05Us
Mirtazapinetablet30 mg/1oralState of Florida DOH Central Pharmacy2009-07-012016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralApotex Corp.2007-08-222016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralCitron Pharma LLC2004-10-222016-04-05Us
Mirtazapinetablet30 mg/1oralContract Pharmacy Services Pa2010-06-302016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralMylan Institutional Inc.2003-08-012016-04-05Us
Mirtazapinetablet, film coated7.5 mg/1oralAurobindo Pharma Limited2004-10-222016-04-05Us
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-09-212016-04-05Us
Mirtazapinetablet30 mg/1oralCardinal Health2004-04-222015-12-29Us
Mirtazapinetablet, film coated45 mg/1oralMylan Pharmaceuticals Inc.2012-12-282016-04-23Us
Mirtazapinetablet, orally disintegrating45 mg/1oralTeva Pharmaceuticals USA Inc2005-09-012016-04-23Us
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2010-11-102016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralSTAT Rx USA LLC2003-06-012016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralRebel Distributors Corp2003-06-012016-04-05Us
Mirtazapinetablet30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-302016-04-23Us
Mirtazapinetablet, film coated15 mg/1oralCardinal Health2007-08-222016-04-05Us
Mirtazapinetablet15 mg/1oralState of Florida DOH Central Pharmacy2009-07-012016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralClinical Solutions Wholesale2007-08-222016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralCitron Pharma LLC2004-10-222016-04-05Us
Mirtazapinetablet, orally disintegrating15 mg/1oralbryant ranch prepack2005-12-082016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralProficient Rx LP2007-08-222016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralMylan Pharmaceuticals Inc.2012-12-282016-04-23Us
Mirtazapinetablet, orally disintegrating30 mg/1oralTeva Pharmaceuticals USA Inc2005-09-012016-04-23Us
Mirtazapinetablet45 mg/1oralREMEDYREPACK INC.2010-09-132016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralSTAT Rx USA LLC2003-06-012016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralRebel Distributors Corp2003-06-012016-04-05Us
Mirtazapinetablet15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-302016-04-23Us
Mirtazapinetablet30 mg/1oralCardinal Health2009-11-302016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralState of Florida DOH Central Pharmacy2013-01-012016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralClinical Solutions Wholesale2007-08-222016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralCitron Pharma LLC2004-10-222016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralbryant ranch prepack2009-08-172016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralDIRECT RX2014-01-012016-04-05Us
Mirtazapinetablet15 mg/1oralContract Pharmacy Services Pa2010-06-302016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralMylan Institutional Inc.2003-08-012016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralTYA Pharmaceuticals2003-06-192016-04-05Us
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2011-08-042016-04-05Us
Mirtazapinetablet7.5 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-222016-04-05Us
Mirtazapinetablet15 mg/1oralCardinal Health2004-04-222015-12-29Us
Mirtazapinetablet45 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-302016-04-23Us
Mirtazapinetablet15 mg/1oralCardinal Health2009-11-302016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralState of Florida DOH Central Pharmacy2009-07-012016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralClinical Solutions Wholesale2003-06-192016-04-05Us
Mirtazapinetablet, film coated7.5 mg/1oralCitron Pharma LLC2004-10-222016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralbryant ranch prepack2003-06-012016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralDIRECT RX2014-01-012016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralAurobindo Pharma Limited2004-10-222016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralMylan Institutional Inc.2003-08-012016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralTYA Pharmaceuticals2007-08-222016-04-05Us
Mirtazapinetablet45 mg/1oralREMEDYREPACK INC.2011-07-222016-04-05Us
Mirtazapinetablet45 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-222016-04-05Us
Mirtazapinetablet30 mg/1oralMc Kesson Contract Packaging2012-01-312016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralMylan Pharmaceuticals Inc.2012-12-282016-04-23Us
Mirtazapinetablet, orally disintegrating15 mg/1oralTeva Pharmaceuticals USA Inc2005-09-012016-04-23Us
Mirtazapinetablet, film coated15 mg/1oralMedsource Pharmaceuticals2009-08-172016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralSTAT Rx USA LLC2003-06-012016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-10-222016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralbryant ranch prepack2009-08-172016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralDIRECT RX2015-01-012016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralAurobindo Pharma Limited2004-10-222016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralUnit Dose Services2003-06-192016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralTYA Pharmaceuticals2009-08-172016-04-05Us
Mirtazapinetablet45 mg/1oralREMEDYREPACK INC.2011-07-182016-04-05Us
Mirtazapinetablet30 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-222016-04-05Us
Mirtazapinetablet15 mg/1oralMc Kesson Contract Packaging2011-10-262016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralEon Labs, Inc.2003-06-192016-04-23Us
Mirtazapinetablet, film coated45 mg/1oralTeva Pharmaceuticals USA Inc2003-06-192016-04-23Us
Mirtazapinetablet, film coated45 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-08-172016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralAurolife Pharma LLC2009-08-172016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-02-192016-04-05Us
Mirtazapinetablet, orally disintegrating45 mg/1oralActavis Pharma, Inc.2014-11-132016-04-23Us
Mirtazapinetablet45 mg/1oralPhysicians Total Care, Inc.2007-08-232016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralState of Florida DOH Central Pharmacy2009-07-012016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralClinical Solutions Wholesale, Llc2007-08-222016-04-05Us
Mirtazapinetablet, film coated7.5 mg/1oralCardinal Health2009-08-172016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralProficient Rx LP2007-08-222016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralREMEDYREPACK INC.2015-03-092016-04-05Us
Mirtazapinetablet, orally disintegrating45 mg/1oralAurobindo Pharma Limited2006-02-282016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-08-282016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-09-142016-04-05Us
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2011-07-182016-04-05Us
Mirtazapinetablet15 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-222016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-162016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralEon Labs, Inc.2003-06-192016-04-23Us
Mirtazapinetablet, film coated30 mg/1oralTeva Pharmaceuticals USA Inc2003-01-292016-04-23Us
Mirtazapinetablet, film coated30 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-08-172016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralAurolife Pharma LLC2009-08-172016-04-05Us
Mirtazapinetablet, film coated30 mg/1oralAidarex Pharmaceuticals LLC2003-06-192016-04-05Us
Mirtazapinetablet, orally disintegrating30 mg/1oralActavis Pharma, Inc.2014-02-112016-04-23Us
Mirtazapinetablet15 mg/1oralPhysicians Total Care, Inc.2006-07-142016-04-05Us
Mirtazapinetablet, film coated15 mg/1oralState of Florida DOH Central Pharmacy2009-07-012016-04-05Us
Mirtazapinetablet, orally disintegrating45 mg/1oralCitron Pharma LLC2006-02-282016-04-05Us
Mirtazapinetablet, film coated45 mg/1oralCardinal Health2009-08-172016-04-05Us
Over the Counter ProductsNot Available
International Brands
NameCompany
AvanzaSchering-Plough
AxitAlphapharm
Mirtabeneratiopharm
MirtazPinewood
MirtazonSchering-Plough
NorsetMSD France
PromyrtilSchering-Plough
RemergilMerck Sharp & Dohme
RemergonOrganon
Remeron SolTabNot Available
RexerSchering-Plough
ZispinOrganon
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIA051Q2099Q
CAS number61337-67-5
WeightAverage: 265.3529
Monoisotopic: 265.157897623
Chemical FormulaC17H19N3
InChI KeyInChIKey=RONZAEMNMFQXRA-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
IUPAC Name
5-methyl-2,5,19-triazatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(15),8,10,12,16,18-hexaene
SMILES
CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as piperazinoazepines. These are compounds containing a piperazinoazepine skeleton, which consists of an azepie ring fused to a piperazine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperazinoazepines
Sub ClassNot Available
Direct ParentPiperazinoazepines
Alternative Parents
Substituents
  • Piperazino-azepine
  • Benzazepine
  • Dialkylarylamine
  • Aralkylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Azepine
  • Imidolactam
  • Benzenoid
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of major depressive disorder.
PharmacodynamicsMirtazapine, an antidepressant of the piperazinoazepine class, is a tetracyclic compound with an anxiolytic effect. Mirtazapine has fewer ADRs than tricyclic antidepressants and is better tolerated. Selective blockade of specific serotonin receptors by mirtazapine likey minimizes side effects typical of other antidepressants.
Mechanism of actionMirtazapine acts as an antagonist at central pre-synaptic alpha(2)-receptors, inhibiting negative feedback to the presynaptic nerve and causing an increase in NE release. Blockade of heteroreceptors, alpha(2)-receptors contained in serotenergic neurons, enhances the release of 5-HT, increasing the interactions between 5-HT and 5-HT1 receptors and contributing to the anxiolytic effects of mirtazapine. Mirtazapine also acts as a weak antagonist at 5-HT1 receptors and as a potent antagonist at 5-HT2 (particularly subtypes 2A and 2C) and 5-HT3 receptors. Blockade of these receptors may explain the lower incidence of adverse effects such as anxiety, insomnia, and nausea. Mirtazapine also exhibits significant antagonism at H1-receptors, resulting in sedation. Mirtazapine has no effects on the reuptake of either NE or 5-HT and has only minimal activity at dopaminergic and muscarinic receptors.
Related Articles
AbsorptionRapid and complete, but, due to first-pass metabolism, absolute bioavailability is 50%.
Volume of distributionNot Available
Protein binding85%
Metabolism

Mirtazapine is extensively metabolized by demethylation and hydroxylation followed by glucuronide conjugation. Cytochrome P450 2D6 and cytochrome P450 1A2 are involved in formation of the 8-hydroxy metabolite of mirtazapine, and cytochrome P450 3A4 is responsible for the formation of the N-desmethyl and N-oxide metabolites. Several metabolites possess pharmacological activity, but plasma levels are very low.

SubstrateEnzymesProduct
Mirtazapine
mirtazapine-N-oxideDetails
Mirtazapine
N-desmethylmirtazapineDetails
Mirtazapine
8-hydroxymirtazapineDetails
Route of eliminationThis drug is known to be substantially excreted by the kidney (75%).
Half life20-40 hours
ClearanceNot Available
ToxicitySymptoms of overdose include disorientation, drowsiness, impaired memory, and tachycardia. LD50 is 600-720mg/kg (oral, mice) and 320-490mg/kg (oral, rat) [PMID: 10333982]
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9873
Blood Brain Barrier+0.9855
Caco-2 permeable+0.7283
P-glycoprotein substrateSubstrate0.8462
P-glycoprotein inhibitor IInhibitor0.6148
P-glycoprotein inhibitor IINon-inhibitor0.8975
Renal organic cation transporterInhibitor0.7956
CYP450 2C9 substrateNon-substrate0.7988
CYP450 2D6 substrateSubstrate0.7894
CYP450 3A4 substrateNon-substrate0.5148
CYP450 1A2 substrateInhibitor0.8503
CYP450 2C9 inhibitorNon-inhibitor0.6675
CYP450 2D6 inhibitorInhibitor0.7222
CYP450 2C19 inhibitorNon-inhibitor0.6206
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6031
Ames testNon AMES toxic0.8079
CarcinogenicityNon-carcinogens0.9742
BiodegradationNot ready biodegradable0.9919
Rat acute toxicity2.5197 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7532
hERG inhibition (predictor II)Inhibitor0.7455
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis totowa llc
  • Aurobindo pharma ltd inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Organon usa inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Watson laboratories inc florida
Packagers
Dosage forms
FormRouteStrength
Tabletoral15 mg/1
Tabletoral30 mg/1
Tabletoral45 mg/1
Tabletoral7.5 mg/1
Tablet, film coatedoral7.5 mg/1
Tabletoral45 mg
Tabletoral30 mg
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral30 mg/1
Tablet, film coatedoral45 mg/1
Tablet (orally disintegrating)oral15 mg
Tablet (orally disintegrating)oral30 mg
Tablet (orally disintegrating)oral45 mg
Tablet, orally disintegratingoral15 mg/1
Tablet, orally disintegratingoral30 mg/1
Tablet, orally disintegratingoral45 mg/1
Tabletoral15 mg
Prices
Unit descriptionCostUnit
Remeron SolTab 30 45 mg Dispersible Tablet Box114.4USD box
Remeron SolTab 30 15 mg Dispersible Tablet Box107.58USD box
Remeron SolTab 30 30 mg Dispersible Tablet Box107.27USD box
Mirtazapine 30 45 mg Dispersible Tablet Box88.95USD box
Mirtazapine 30 30 mg Dispersible Tablet Box83.48USD box
Mirtazapine 30 15 mg Dispersible Tablet Box81.02USD box
Remeron 45 mg tablet4.61USD tablet
Remeron 15 mg tablet4.42USD tablet
Remeron 45 mg soltab3.57USD tablet
Remeron 30 mg soltab3.55USD tablet
Remeron 30 mg tablet3.47USD tablet
Remeron 15 mg soltab3.26USD tablet
Mirtazapine 45 mg tablet2.91USD tablet
Mirtazapine 30 mg tablet2.85USD tablet
Mirtazapine 15 mg tablet2.77USD tablet
Mirtazapine 7.5 mg tablet2.56USD tablet
Apo-Mirtazapine 30 mg Tablet0.73USD tablet
Mylan-Mirtazapine 30 mg Tablet0.73USD tablet
Novo-Mirtazapine 30 mg Tablet0.73USD tablet
Phl-Mirtazapine 30 mg Tablet0.73USD tablet
Pms-Mirtazapine 30 mg Tablet0.73USD tablet
Ratio-Mirtazapine 30 mg Tablet0.73USD tablet
Sandoz Mirtazapine 30 mg Tablet0.73USD tablet
Pms-Mirtazapine 15 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2386547 No2010-06-082020-10-09Canada
US5178878 No1993-01-122010-01-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point114-116 °CNot Available
water solubilitySlightNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.1 mg/mLALOGPS
logP2.9ALOGPS
logP3.21ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)6.67ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area19.37 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity82.66 m3·mol-1ChemAxon
Polarizability30.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Leonid Metzger, “Methods for the preparation of mirtazapine intermediates.” U.S. Patent US20020165238, issued November 07, 2002.

US20020165238
General References
  1. Gillman PK: A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol. 2006 Mar;21(2):117-25. [PubMed:16342227 ]
  2. Burrows GD, Kremer CM: Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997 Apr;17 Suppl 1:34S-39S. [PubMed:9090576 ]
  3. Velazquez C, Carlson A, Stokes KA, Leikin JB: Relative safety of mirtazapine overdose. Vet Hum Toxicol. 2001 Dec;43(6):342-4. [PubMed:11757992 ]
  4. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735 ]
  5. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. [PubMed:16272179 ]
  6. Fawcett J, Barkin RL: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998 Dec;51(3):267-85. [PubMed:10333982 ]
External Links
ATC CodesN06AX11
AHFS Codes
  • 28:16.04.92
PDB EntriesNot Available
FDA labelDownload (904 KB)
MSDSDownload (57.2 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Mirtazapine can be increased when it is combined with Abiraterone.
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ApraclonidineMirtazapine may decrease the antihypertensive activities of Apraclonidine.
AprepitantThe serum concentration of Mirtazapine can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AzelastineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BexaroteneThe serum concentration of Mirtazapine can be decreased when it is combined with Bexarotene.
BortezomibThe metabolism of Mirtazapine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Mirtazapine can be decreased when it is combined with Bosentan.
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BrimonidineMirtazapine may decrease the antihypertensive activities of Brimonidine.
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BuprenorphineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CarbamazepineThe metabolism of Mirtazapine can be increased when combined with Carbamazepine.
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CitalopramMirtazapine may increase the QTc-prolonging activities of Citalopram.
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClonidineMirtazapine may decrease the antihypertensive activities of Clonidine.
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ConivaptanThe serum concentration of Mirtazapine can be increased when it is combined with Conivaptan.
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Cyproterone acetateThe serum concentration of Mirtazapine can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Mirtazapine can be decreased when it is combined with Dabrafenib.
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Mirtazapine.
DasatinibThe serum concentration of Mirtazapine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Mirtazapine can be decreased when it is combined with Deferasirox.
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Dexchlorpheniramine maleateDexchlorpheniramine maleate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DexmedetomidineMirtazapine may decrease the antihypertensive activities of Dexmedetomidine.
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DipivefrinMirtazapine may decrease the antihypertensive activities of Dipivefrin.
DofetilideMirtazapine may increase the QTc-prolonging activities of Dofetilide.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FluconazoleThe metabolism of Mirtazapine can be decreased when combined with Fluconazole.
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FluoxetineThe metabolism of Mirtazapine can be decreased when combined with Fluoxetine.
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FluvoxamineThe metabolism of Mirtazapine can be decreased when combined with Fluvoxamine.
FosaprepitantThe serum concentration of Mirtazapine can be increased when it is combined with Fosaprepitant.
Fusidic AcidThe serum concentration of Mirtazapine can be increased when it is combined with Fusidic Acid.
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
GoserelinMirtazapine may increase the QTc-prolonging activities of Goserelin.
GranisetronGranisetron may increase the serotonergic activities of Mirtazapine.
GuanfacineMirtazapine may decrease the antihypertensive activities of Guanfacine.
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HydrocodoneMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
IdelalisibThe serum concentration of Mirtazapine can be increased when it is combined with Idelalisib.
IsocarboxazidIsocarboxazid may increase the central neurotoxic activities of Mirtazapine.
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
IvacaftorThe serum concentration of Mirtazapine can be increased when it is combined with Ivacaftor.
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Mirtazapine.
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LeuprolideMirtazapine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LinezolidLinezolid may increase the serotonergic activities of Mirtazapine.
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LuliconazoleThe serum concentration of Mirtazapine can be increased when it is combined with Luliconazole.
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethotrimeprazineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethyldopaMirtazapine may decrease the antihypertensive activities of Methyldopa.
Methylene blueMirtazapine may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Metoclopramide.
MetyrosineMirtazapine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mirtazapine can be decreased when combined with Mexiletine.
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MifepristoneThe serum concentration of Mirtazapine can be increased when it is combined with Mifepristone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MitotaneThe serum concentration of Mirtazapine can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the central neurotoxic activities of Mirtazapine.
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NelfinavirThe metabolism of Mirtazapine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Mirtazapine can be increased when it is combined with Netupitant.
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OrphenadrineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PalbociclibThe serum concentration of Mirtazapine can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Mirtazapine can be increased when it is combined with Panobinostat.
ParaldehydeMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Peginterferon alfa-2bThe serum concentration of Mirtazapine can be decreased when it is combined with Peginterferon alfa-2b.
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PhenelzinePhenelzine may increase the central neurotoxic activities of Mirtazapine.
PhenytoinThe metabolism of Mirtazapine can be increased when combined with Phenytoin.
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PramipexoleMirtazapine may increase the sedative activities of Pramipexole.
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ProcarbazineProcarbazine may increase the central neurotoxic activities of Mirtazapine.
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RasagilineRasagiline may increase the central neurotoxic activities of Mirtazapine.
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RitonavirThe metabolism of Mirtazapine can be decreased when combined with Ritonavir.
RopiniroleMirtazapine may increase the sedative activities of Ropinirole.
RotigotineMirtazapine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Mirtazapine.
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Scopolamine butylbromideScopolamine butylbromide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SelegilineSelegiline may increase the central neurotoxic activities of Mirtazapine.
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SiltuximabThe serum concentration of Mirtazapine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Mirtazapine can be increased when it is combined with Simeprevir.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
St. John's WortThe serum concentration of Mirtazapine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Mirtazapine can be increased when it is combined with Stiripentol.
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SuvorexantMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Mirtazapine.
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TeriflunomideThe serum concentration of Mirtazapine can be decreased when it is combined with Teriflunomide.
ThalidomideMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TiclopidineThe metabolism of Mirtazapine can be decreased when combined with Ticlopidine.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Mirtazapine.
TocilizumabThe serum concentration of Mirtazapine can be decreased when it is combined with Tocilizumab.
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mirtazapine.
TranylcypromineTranylcypromine may increase the central neurotoxic activities of Mirtazapine.
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
VemurafenibThe serum concentration of Mirtazapine can be increased when it is combined with Vemurafenib.
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
WarfarinMirtazapine may increase the anticoagulant activities of Warfarin.
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZolpidemMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. [PubMed:10446734 ]
  2. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735 ]
  3. Nutt DJ: Care of depressed patients with anxiety symptoms. J Clin Psychiatry. 1999;60 Suppl 17:23-7; discussion 46-8. [PubMed:10446738 ]
  4. Laakmann G, Schule C, Baghai T, Waldvogel E: Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology. 1999 Oct;24(7):769-84. [PubMed:10451911 ]
  5. Waldinger MD, Berendsen HH, Schweitzer DH: Treatment of hot flushes with mirtazapine: four case reports. Maturitas. 2000 Oct 31;36(3):165-8. [PubMed:11063897 ]
  6. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. [PubMed:10446734 ]
  2. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735 ]
  3. Kast RE, Foley KF: Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl). 2007 Jul;16(4):351-4. [PubMed:17587360 ]
  4. de Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. [PubMed:8930006 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Garcia-Sevilla JA, Ventayol P, Perez V, Rubovszky G, Puigdemont D, Ferrer-Alcon M, Andreoli A, Guimon J, Alvarez E: Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology. 2004 Mar;29(3):580-8. [PubMed:14628003 ]
  2. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
  3. Besson A, Haddjeri N, Blier P, de Montigny C: Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol. 2000 May;10(3):177-88. [PubMed:10793320 ]
  4. Schreiber S, Bleich A, Pick CG: Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects--a possible opioid involvement in severe depression? J Mol Neurosci. 2002 Feb-Apr;18(1-2):143-9. [PubMed:11931344 ]
  5. Rogoz Z, Wrobel A, Dlaboga D, Maj J, Dziedzicka-Wasylewska M: Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors. J Physiol Pharmacol. 2002 Mar;53(1):105-16. [PubMed:11939713 ]
  6. Rogoz Z, Wrobel A, Dlaboga D, Dziedzicka-Wasylewska M: Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. Pol J Pharmacol. 2002 Jul-Aug;54(4):381-9. [PubMed:12523492 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Benelli A, Frigeri C, Bertolini A, Genedani S: Influence of mirtazapine on the sexual behavior of male rats. Psychopharmacology (Berl). 2004 Jan;171(3):250-8. Epub 2003 Nov 13. [PubMed:14615872 ]
  2. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
  3. Meert TF, Melis W, Aerts N, Clincke G: Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats. Behav Pharmacol. 1997 Aug;8(4):353-63. [PubMed:9832994 ]
  4. Millan MJ: Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. [PubMed:16433010 ]
  5. Dekeyne A, Iob L, Millan MJ: Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats. Psychopharmacology (Berl). 2001 Jan;153(3):389-92. [PubMed:11271412 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Schreiber S, Rigai T, Katz Y, Pick CG: The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms. Brain Res Bull. 2002 Sep 30;58(6):601-5. [PubMed:12372565 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  3. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binding
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  3. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  3. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. [PubMed:12109911 ]
  4. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. [PubMed:12109911 ]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. [PubMed:12109911 ]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. de Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57 Suppl 4:19-25. [PubMed:8636062 ]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  4. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  3. de Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. [PubMed:8930006 ]
  4. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system. Signals through the inhibition of adenylate cyclase and displays high constitutive activity (spontaneous activity in the absence of agonist). Agonist stimulation of isoform 3 neither modified adenylate cyclase activity nor induced intracellular calcium mobilization.
Gene Name:
HRH3
Uniprot ID:
Q9Y5N1
Molecular Weight:
48670.81 Da
References
  1. Pytliak M, Vargova V, Mechirova V, Felsoci M: Serotonin receptors - from molecular biology to clinical applications. Physiol Res. 2011;60(1):15-25. Epub 2010 Oct 15. [PubMed:20945968 ]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  4. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 21, 2016 09:43